A Phase 3 interventional study of givinostat and placebo in Duchenne Muscular Dystrophy, sponsored by Italfarmaco. Completed at 42 sites in 11 countries. Open to male participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-02-02.
Sponsored by Italfarmaco · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 232 studies in Muscular Dystrophy, Duchenne with a site in United States — 34 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.
Among the 232 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 13th largest by enrollment of the 171 interventional ones that give a count, is one of 11 that started in 2017, is one of 32 in phase 3, and was the 106th registered.
481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 106 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →34 of the 232 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
University of Florida · Sites in United States
Ages 6+ · Men only
Vanderbilt University Medical Center · Sites in United States
Ages 8–18 · Men only
University of Rochester · Sites in United States
Ages 0 days–3 yrs · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.
This study: 6 Years to 17 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
232 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 57 · Phase 2 90 · Phase 3 40 · Phase 4 5
First in 2000; this study’s year is marked. 11 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 179 is above the median of 26 across 332 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 25 across the 171 interventional studies, 75 across the 55 observational. Of the 160 that completed or were terminated, 78 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
130 of 232 have an industry lead sponsor. The 10 most frequent:
Italfarmaco is the lead sponsor of 35 studies on the registry; 5 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Italfarmaco has 8 studies filed under Muscular Dystrophy, Duchenne — fewer than ten, so there is no comparison to draw.
20 of the studies in Muscular Dystrophy, Duchenne with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT06290713University of FloridaVasodilator and Exercise Study for DMD (VASO-REx) | 2026-11 |
| NCT06450639Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD) | 2026-11-18 |
| NCT03368742Solid Biosciences Inc.Microdystrophin Gene Transfer Study in Adolescents and Children With DMD | 2026-11-30 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Add all 20 to your calendar (.ics) → With an account.
Among the 232 studies in Muscular Dystrophy, Duchenne with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objective
The primary objective of the study was to establish the effects of givinostat versus placebo administered chronically over 18 months to slow disease progression in ambulant DMD subjects.
Secondary Objectives
The secondary objectives of this study were:
This was a phase 3, randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of givinostat in ambulant subjects with DMD. This study included ambulant male paediatric subjects aged ≥ 6 years at baseline affected by DMD.
A total of 179 male ambulant subjects was randomized 2:1 (givinostat: placebo).
Subjects were stratified for their concomitant use of steroids in 4 strata:
Givinostat or placebo oral suspension (10 mg/mL) was administered orally as 2 oral doses daily while the subject were in fed state, according to the child's weight.
Study drug should have been permanently stopped if any of the following occurred:
Study drug should have been temporarily stopped if any of the following occurred:
In case the study drug was temporarily stopped, the study drug could be resumed at a level 20% smaller than the one at which the Adverse Event leading to temporary stop occurred, once platelets and/or white blood cell and/or hemoglobin normalized and/or triglycerides returned to levels below 300 mg/dL (3.42 mmol/L) or diarrhoea was mild.
In addition, in case a subject had a consistent (e.g., at least 2 consecutive evaluations) platelets count ≤150 x 10\^9/L and didn't meet the stopping criteria for platelets, the Investigator should have to reduce the dose by 20% of the current dose.
Only one dose reduction was allowed during the treatment period.
This trial design a single planned interim analysis. The interim was governed by an IDMC in order to solely assess futility.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
At the discretion of the Investigator, subjects not meeting inclusion/exclusion criteria may be re-screened twice with an interval of at least 3 months between assessments.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Givinostat oral suspension (10 mg/mL) twice daily
Drug: givinostat
Placebo oral suspension (10 mg/mL) twice daily
Drug: placebo
The oral suspension of givinostat (10 mg/mL) was to be dosed in fed condition as described below: Givinostat or placebo starting dose * \> or =10 and \< 12.5 kg of weight: 13.3 mg bid = 1.3 ml oral suspension bid * \> or =12.5 and \< 20 kg: 16.7 mg bid =1.7 ml oral suspension bid * \> or = 20 and \< 25 kg: 20 mg bid = 2.0 ml oral suspension bid * \> or = 25 and \< 30 kg: 23.3 mg bid = 2.3 ml oral suspension bid * \> or = 30 and \< 40 kg: 26.7 mg bid = 2.7 ml oral suspension bid * \> or = 40 and \< 50 kg: 33.3 mg bid = 3.3 ml oral suspension bid * \> or = 50 and \< 60 kg: 36.7 mg bid = 3.7 ml oral suspension bid * \> or = 60 and \< 70 kg: 40 mg bid = 4 ml oral suspension bid * \> or = 70 kg: 46.7 mg bid = 4.7 ml oral suspension bid
Also known as: ITF2357
The oral suspension of placebo, manufactured to mimic givinostat, was to be dosed in fed condition as described for givinostat.
Mean Change From Baseline in 4 Standard Stairs (4SC) Climb After 18 Months of Treatment
The time (in seconds) to climb 4 standard-sized stairs is a TFT that represents stair-climbing ability. The test was evaluated by qualified functional evaluators (ie, physiotherapists) who were different from the site personnel who reviewed subjects' safety results. The test was performed in a standardised manner described in a specific site manual. Baseline 4SC was the measurement taken at the randomization assessment, unless this was missing, in which case baseline was taken as the last non missing value recorded prior to or on the date of first study treatment. The shorter the time, the better the outcome.
Time frame: Baseline and 18 months
Mean Change From Baseline in Time to Rise From Floor After 18 Months of Treatment
An analysis of time (in seconds) to rise from the floor by change from baseline at 18 months is presented for the Target Population in the ITT analysis set. The shorter the time, the better the outcome.
Time frame: Baseline and 18 months
Mean Change From Baseline in the Six-minute Walking Test (6MWT) After 18 Months of Treatment
This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. The 6-Minute Walk Test is a useful measure of functional capacity targeted at people with at least moderately severe impairment. A modified version of the 6MWT recommended by American Thoracic Society (2002) for use in adults was performed. The longer the walked distance the better the outcome.
Time frame: Baseline and 18 months
Mean Change From Baseline in Total North Star Ambulatory Assessment (NSAA) Score After 18 Months of Treatment
The total North Star Ambulatory Assessment (NSAA) is a 17-item rating scale that is used to measure functional motor abilities in ambulant children with Duchenne Muscular Dystrophy (DMD). It is usually used to monitor the progression of the disease and treatment effects. The 17 items of the NSAA, ranging from standing to running 10 meters, were graded using the standard score card with each assessment rated as 0 - unable to achieve independently, 1 - modified method but achieves goal independent of physical assistance from another, or 2 - normal with no obvious modification of activity. This scale is ordinal with 0 as the minimum score (indicating full disfunctionality, i.e. the worst outcome) and with 34 as the maximum score indicating fully-independent function (the best outcome).
Time frame: Baseline and 18 months
Cumulative Loss of Function on the NSAA
Subject cumulative number of failures across all postbaseline visits was the endpoint of interest for analysis. For each subject at each postbaseline visit, failure to perform each of the 17 items of the NSAA was assessed, where "failure" was defined as a score transition from 2 or 1 at baseline to 0 at the respective visit. The total number of failed items for the visit was calculated (maximum of 17 failed items per visit per subject). The subject's cumulative number of failures across all visits was the sum of the total failures at each postbaseline visit.
Time frame: over 18 months
Mean Change From Baseline of Muscle Strength Normalized Overtime
The mean change of muscle strength normalized was evaluated by knee extension and elbow flexion normalized by subject weight, both measured by hand-held myometry (HHM).
Time frame: Baseline and 18 months
Mean Change From Baseline in Vastus Lateralis Muscle Fat Fraction (VL MFF) at 18 Months
Vastus lateralis muscle fat fraction (VL MFF) was expressed as fat infiltration in this muscle. Fat infiltration was assessed by Magnetic Resonance (MRS).
Time frame: Baseline and 18 months
Number of Subjects Experiencing Treatment-emergent AEs (TEAEs), Serious AEs (SAEs), Mild TEAE Moderate TEAE, Severe TEAE
Adverse Events are unfavorable changes in health, including abnormal laboratory findings, that occur in trial participants during the clinical trial or within a specified period following the trial. Serious Adverse Events include adverse events that result in death, require either inpatient hospitalization or the prolongation of hospitalization, are life-threatening, result in a persistent or significant disability/incapacity or result in a congenital anomaly/birth defect. Other important medical events, based upon appropriate medical judgment, may also be considered Serious Adverse Events if a trial participant's health is at risk and intervention is required to prevent an outcome mentioned.
Time frame: Baseline through end of study, that is the end of 18° month
Evaluation of Acceptability/Palatability of the Oral Suspension
Acceptability and palatability of the oral suspension over time are presented. More in details, child perception of the medicine at the three timepoints hereunder specified; parent perception of the medicine based on the child's reaction at the same three timepoints; and parent problems administering the medication at the same timepoints are reported.
Time frame: Week 4, EOS, early withdrawal
Within the overall population, a total of 118 subjects were enrolled in the givinostat group. A total of 61 subjects were enrolled in the placebo group.
| Milestone | Givinostat | Placebo |
|---|---|---|
| Started | 118 | 61 |
| All enrolled subjects | 118 | 61 |
| Itt population | 118 | 61 |
| Safety set | 118 | 61 |
| Pk analysis set | 117 | 0 |
| Target population | 81 | 39 |
| Mr cohort | 77 | 37 |
| Completed | 111 | 59 |
| Not completed | 7 | 2 |
| Withdrew: Withdrawal by subject | 4 | 2 |
| Withdrew: Adverse event | 3 | 0 |
The time (in seconds) to climb 4 standard-sized stairs is a TFT that represents stair-climbing ability. The test was evaluated by qualified functional evaluators (ie, physiotherapists) who were different from the site personnel who reviewed subjects' safety results. The test was performed in a standardised manner described in a specific site manual. Baseline 4SC was the measurement taken at the randomization assessment, unless this was missing, in which case baseline was taken as the last non missing value recorded prior to or on the date of first study treatment. The shorter the time, the better the outcome.
| seconds | Givinostat | Placebo |
|---|---|---|
| Mean Change From Baseline in 4 Standard Stairs (4SC) Climb After 18 Months of Treatment | 1.27 ± 0.040 | 1.48 ± 0.058 |
An analysis of time (in seconds) to rise from the floor by change from baseline at 18 months is presented for the Target Population in the ITT analysis set. The shorter the time, the better the outcome.
| seconds | Givinostat | Placebo |
|---|---|---|
| Mean Change From Baseline in Time to Rise From Floor After 18 Months of Treatment | 9.33 (5.821 to 12.838) | 12.61 (7.491 to 17.724) |
This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. The 6-Minute Walk Test is a useful measure of functional capacity targeted at people with at least moderately severe impairment. A modified version of the 6MWT recommended by American Thoracic Society (2002) for use in adults was performed. The longer the walked distance the better the outcome.
| meters | Givinostat | Placebo |
|---|---|---|
| Mean Change From Baseline in the Six-minute Walking Test (6MWT) After 18 Months of Treatment | -38.43 (-50.704 to -26.153) | -48.38 (-66.288 to -30.482) |
The total North Star Ambulatory Assessment (NSAA) is a 17-item rating scale that is used to measure functional motor abilities in ambulant children with Duchenne Muscular Dystrophy (DMD). It is usually used to monitor the progression of the disease and treatment effects. The 17 items of the NSAA, ranging from standing to running 10 meters, were graded using the standard score card with each assessment rated as 0 - unable to achieve independently, 1 - modified method but achieves goal independent of physical assistance from another, or 2 - normal with no obvious modification of activity. This scale is ordinal with 0 as the minimum score (indicating full disfunctionality, i.e. the worst outcome) and with 34 as the maximum score indicating fully-independent function (the best outcome).
| score on a scale | Givinostat | Placebo |
|---|---|---|
| Mean Change From Baseline in Total North Star Ambulatory Assessment (NSAA) Score After 18 Months of Treatment | -2.66 (-3.563 to -1.759) | -4.58 (-5.891 to -3.260) |
Subject cumulative number of failures across all postbaseline visits was the endpoint of interest for analysis. For each subject at each postbaseline visit, failure to perform each of the 17 items of the NSAA was assessed, where "failure" was defined as a score transition from 2 or 1 at baseline to 0 at the respective visit. The total number of failed items for the visit was calculated (maximum of 17 failed items per visit per subject). The subject's cumulative number of failures across all visits was the sum of the total failures at each postbaseline visit.
| cumulative number of failures | Givinostat | Placebo |
|---|---|---|
| Cumulative Loss of Function on the NSAA | 3.42 (2.692 to 4.334) | 5.56 (4.002 to 7.715) |
The mean change of muscle strength normalized was evaluated by knee extension and elbow flexion normalized by subject weight, both measured by hand-held myometry (HHM).
| Newtons/kg | Givinostat | Placebo |
|---|---|---|
| Overall knee extension | -0.32 (-0.441 to -0.197) | -0.50 (-0.681 to -0.328) |
| Overall elbow flexion | -0.10 (-0.174 to -0.031) | -0.19 (-0.292 to -0.085) |
Vastus lateralis muscle fat fraction (VL MFF) was expressed as fat infiltration in this muscle. Fat infiltration was assessed by Magnetic Resonance (MRS).
| percentage of fat | Givinostat | Placebo |
|---|---|---|
| Mean Change From Baseline in Vastus Lateralis Muscle Fat Fraction (VL MFF) at 18 Months | 7.63 (6.098 to 9.172) | 10.56 (8.331 to 12.783) |
Adverse Events are unfavorable changes in health, including abnormal laboratory findings, that occur in trial participants during the clinical trial or within a specified period following the trial. Serious Adverse Events include adverse events that result in death, require either inpatient hospitalization or the prolongation of hospitalization, are life-threatening, result in a persistent or significant disability/incapacity or result in a congenital anomaly/birth defect. Other important medical events, based upon appropriate medical judgment, may also be considered Serious Adverse Events if a trial participant's health is at risk and intervention is required to prevent an outcome mentioned.
| Participants | Givinostat | Placebo |
|---|---|---|
| Subjects with TEAE | 112 | 57 |
| Subjects with serious AE | 8 | 2 |
| Subjects with mild AE | 69 | 39 |
| Subjects with moderate AE | 38 | 17 |
| Subjects with severe AE | 5 | 1 |
Acceptability and palatability of the oral suspension over time are presented. More in details, child perception of the medicine at the three timepoints hereunder specified; parent perception of the medicine based on the child's reaction at the same three timepoints; and parent problems administering the medication at the same timepoints are reported.
| Participants | Givinostat | Placebo |
|---|---|---|
| Child perception - week 4 - dislike very much | 31 | 11 |
| Child perception - week 4 - dislike a little | 21 | 17 |
| Child perception - week 4 - not sure | 30 | 16 |
| Child perception - week 4 - like a little | 19 | 12 |
| Child perception - week 4 - like very much | 11 | 3 |
| Child perception - EOS - dislike very much | 21 | 7 |
| Child perception - EOS - dislike a little | 24 | 13 |
| Child perception - EOS - not sure | 34 | 16 |
| Child perception - EOS - like a little | 19 | 10 |
| Child perception - EOS - like very much | 7 | 9 |
| Child perception - early withdrawal - dislike very much | 1 | 0 |
| Child perception - early withdrawal - dislike a little | 1 | 0 |
| Child perception - early withdrawal - not sure | 2 | 0 |
| Child perception - early withdrawal - like a little | 1 | 0 |
| Child perception - early withdrawal - like very much | 0 | 0 |
| Parent perception - week 4 - unpleasant | 50 | 31 |
| Parent perception - week 4 - not sure | 28 | 10 |
| Parent perception - week 4 - pleasant | 35 | 18 |
| Parent perception - EOS - unpleasant | 42 | 14 |
| Parent perception - EOS - not sure | 40 | 22 |
| Parent perception - EOS - pleasant | 26 | 19 |
| Parent perception - early withdrawal - unpleasant | 1 | 0 |
| Parent perception - early withdrawal - not sure | 3 | 0 |
| Parent perception - early withdrawal - pleasant | 1 | 0 |
| Parent admin problems - week 4 - yes | 6 | 1 |
| Parent admin problems - week 4 - no | 107 | 58 |
| Parent admin problems - EOS - yes | 5 | 0 |
| Parent admin problems - EOS - no | 102 | 55 |
| Parent admin - early withdrawal - yes | 0 | 0 |
| Parent admin - early withdrawal - no | 5 | 0 |
Collected over Throughout the study till the end of study (month 18, visit 15). More precisely at Visits 4 and 7 (month 1), at Visit 9 (month 2), at Visit 10 (month 3), at Visit 11 (month 6), at Visit 12 (month 9), at Visit 13 (month 12), at Visit 14 (month 15), at Visit 15 (EOS, month 18) and at the FUV (Follow-Up Visit to be performed after 4 weeks from the last dose of study drug (ie, 4 weeks ± 7 days)).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Givinostat | 0/118 (0%) | 8/118 (6.8%) | 112/118 (94.9%) |
| Placebo | 0/61 (0%) | 2/61 (3.3%) | 57/61 (93.4%) |
| Event | Givinostat | Placebo |
|---|---|---|
| GastroenteritisInfections and infestations | 1/118 | 2/61 |
| Gastroenteritis viralInfections and infestations | 1/118 | 0/61 |
| InfluenzaInfections and infestations | 1/118 | 0/61 |
| Abdominal painGastrointestinal disorders | 1/118 | 0/61 |
| VomitingGastrointestinal disorders | 1/118 | 0/61 |
| Chest painGeneral disorders | 1/118 | 0/61 |
| Spinal fractureInjury, poisoning and procedural complications | 1/118 | 0/61 |
| DizzinessNervous system disorders | 1/118 | 0/61 |
| RashSkin and subcutaneous tissue disorders | 1/118 | 0/61 |
| Event | Givinostat | Placebo |
|---|---|---|
| Platelet count decreasedInvestigations | 51/118 | 9/61 |
| DiarrhoeaGastrointestinal disorders | 43/118 | 11/61 |
| NasopharyngitisInfections and infestations | 31/118 | 19/61 |
| VomitingGastrointestinal disorders | 34/118 | 8/61 |
| HeadacheNervous system disorders | 28/118 | 14/61 |
| FallInjury, poisoning and procedural complications | 15/118 | 13/61 |
| Abdominal painGastrointestinal disorders | 25/118 | 9/61 |
| ThrombocytopeniaBlood and lymphatic system disorders | 19/118 | 0/61 |
| CoughRespiratory, thoracic and mediastinal disorders | 13/118 | 9/61 |
| Abdominal pain upperGastrointestinal disorders | 17/118 | 7/61 |
Number of Subjects Enrolled in Each Country (Overall Population).The all-enrolled subjects set included all subjects who were randomised to study treatment. The overall all-enrolled subjects set included all subjects in both the target and off-target populations (Group A + Group B) who were randomised to study treatment.
| Age, Categorical(Participants) | Givinostat | Placebo | Total |
|---|---|---|---|
| <=18 years | 118 | 61 | 179 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Givinostat | Placebo | Total |
|---|---|---|---|
| Mean | 9.78 ± 2.022 | 9.97 ± 2.082 | 9.84 ± 2.039 |
| Sex: Female, Male(Participants) | Givinostat | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 118 | 61 | 179 |
| Ethnicity (NIH/OMB)(Participants) | Givinostat | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 3 | 12 |
| Not Hispanic or Latino | 109 | 58 | 167 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Givinostat | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 2 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 0 | 3 |
| White | 106 | 57 | 163 |
| More than one race | 5 | 2 | 7 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Givinostat | Placebo | Total |
|---|---|---|---|
| Canada | 9 | 6 | 15 |
| Netherlands | 5 | 3 | 8 |
| Belgium | 6 | 3 | 9 |
| United States | 24 | 19 | 43 |
| Italy | 24 | 13 | 37 |
| United Kingdom | 10 | 3 | 13 |
| Israel | 1 | 0 | 1 |
| France | 9 | 5 | 14 |
| Serbia | 0 | 1 | 1 |
| Germany | 13 | 2 | 15 |
| Spain | 17 | 6 | 23 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2017 to primary completion in Feb 2022, 56 months.
Results were first posted in Feb 2023, 11 months after primary completion.
Of 26 phase 3 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's 56 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Givinostat
Muscular Dystrophy, Duchenne →